Ann: Phase 1 CF33-hNIS Study Update - Positive Early Signals, page-40

May have been released before but market still not listening?? ???

Only so many ways you can say it works when you can't say it works!!!

Imagine the stats if early diagnosed patients had been administered !!!

"Early results presented this week at the annual ASCO-GI Symposium in San
Francisco, California, show that 7 patients with gastrointestinal cancers who
received CF33-hNIS alone including 3 colorectal, 2 biliary tract, 1 pancreatic and 1
liver cancer showed positive treatment effects, with a disease control rate (all CR,
PR and SD) of 86%. Importantly, in these patients, changes in tumour burden
correlated with systemic immunological changes known to promote anti-tumour
immunity."